BioSpace News Archive

Bayer further expands the global clinical development program for NUBEQA® (darolutamide) in prostate cancer.

Masimo Corporation announced changes to its Board of Directors and governance policies, the result of an ongoing board refreshment and governance review process informed by regular engagement with stockholders.

The Lupus Research Alliance (LRA) today announced the recipients of the newest Lupus Innovation Award (LIA) grants.

At this year’s Fruit Logistica taking place in Berlin from February 8-10 Bayer highlights its solutions towards regenerative agriculture, meaning the balance between productivity outcomes and environmental protection, while supporting the needs of society and farmers.

Entera Bio Ltd. announced today that it received notice from The NASDAQ Stock Market LLC (NASDAQ) on March 23, 2023, informing Entera that it has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550(a)(2) for continued listing on The NASDAQ Capital Market.

Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the “Company” or “Sona”) announces that it has closed its previously announced acquisition of Siva Therapeutics, Inc. (“Siva”). Pursuant to the share exchange agreement announced on January 26, 2023,

Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (“Therma” or the “Company”), developer and investor in a range of leading-edge, proprietary diagnostic and medical device technologies, is pleased to announce that the Company and AI4LYF are preparing to launch DCT, its digital cough data collection and screening smartphone application.

Houston-based DM Clinical Research, a national network of clinical trial sites, is seeking parents willing to enroll children and adolescents in pediatric studies focused on COVID-19, Lyme disease, migraine headaches and respiratory syncytial virus (RSV).

Volpara Health Technologies Ltd., a global leader in software for the early detection of cancer, is attending this year’s National Consortium of Breast Centers conference in Las Vegas to showcase its software advancements that are powering ‘s progressive breast centers.

Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, announced today that it has completed CHF 40M in Series D1 funding.